Bio Pharma Dive
NOVEMBER 7, 2022
Buoyed by strong mid-stage study results, the biotech will soon start a cardiovascular outcomes trial of a drug designed to target a genetic risk factor called lipoprotein(a).
XTalks
SEPTEMBER 11, 2020
A study published in JAMA Oncology found that in cancer drug trials conducted between 2008 and 2018, nearly two-thirds of participants were non-Hispanic whites. When trial populations don’t match the broader patient base, the treatments they produce aren’t as effective. Nearly all diseases have a genetic component.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 25, 2022
Obesity, diabetes, and genetics are the primary drivers, and COVID is about to make this exponentially worse. But herein lies the dichotomy that medicine has created: By failing to regularly screen to find the early-stage disease, the number of patients who could participate in drug trials is limited.
XTalks
MAY 16, 2023
The exact cause of pulmonary fibrosis is often unknown, and in such cases, it is referred to as idiopathic pulmonary fibrosis (IPF); however, certain factors can contribute to the development of pulmonary fibrosis, including environmental and occupational exposures, certain medications, autoimmune diseases and genetic predisposition.
Pharmaceutical Technology
JUNE 15, 2023
AI can also speed up crucial steps in the pharma R&D process, such as the discovery process for novel drug compounds or the design of clinical drug trials. AI can help identify specific patient populations that are most likely to benefit from a particular drug based on factors such as genetic makeup and lifestyle.
XTalks
FEBRUARY 25, 2022
Despite these statistics, in the US, Black people only constitute five percent of all clinical trial participants. The overwhelming majority of trial participants nationwide are white. However, the links between race-based genetics and disease are not quite clear. Personalized Medicine.
XTalks
SEPTEMBER 13, 2024
Generalizability: Determining if results from a diverse participant group can be applied more broadly across various populations outside the trial. Scientific Validity: Ensuring that diverse genetic backgrounds are considered, which can influence how patients metabolize drugs and respond to therapies.
Expert insights. Personalized for you.
282 
Let's personalize your content